Superluminal Medicines Secures $60M in Series B Funding Round

Superluminal Medicines, a Boston, MA-based biotechnology company integrating AI/ML, protein dynamics, and structural biology to generate G protein-coupled receptor (GPCR) targets, has raised $60 million in a Series B financing round led by BVF Partners, L.P.

The round also saw participation from new investors Deep Track Capital and Perceptive Advisors, along with existing investors RA Capital Management, Insight Partners, NVIDIA, Catalio Capital Management, Eli Lilly and Company, Cooley, and Gaingels.

The company will use the funding to advance its obesity program, expand its drug pipeline, and develop new small-molecule therapies for endocrine and cardiometabolic diseases.

Funding Snapshot

About Superluminal Medicines

Superluminal Medicines combines structural biology, machine learning, computational chemistry and medicinal chemistry to accelerate small-molecule drug discovery. The company initially focused on G protein-coupled receptors (GPCRs), a complex class of drug targets involved in many biological processes.

Read More:Oregon-Based Resect AI Raises $25M in Funding

Its technology platform combines structural data, machine learning, GPCR-focused models, molecular design and predictive safety tools to identify potential drug candidates.

Core offerings include:

• AI-powered small molecule drug discovery
• GPCR target discovery
• Structural biology and Cryo-EM
• Computational drug design

Core Technologies / Products / Services